Thompson Siegel & Walmsley LLC Reduces Holdings in Pfizer Inc. (NYSE:PFE)

Thompson Siegel & Walmsley LLC lessened its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 19.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 387,084 shares of the biopharmaceutical company's stock after selling 92,801 shares during the quarter. Thompson Siegel & Walmsley LLC's holdings in Pfizer were worth $11,202,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Olistico Wealth LLC bought a new stake in shares of Pfizer in the 2nd quarter valued at approximately $25,000. Gladius Capital Management LP raised its stake in shares of Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 38,015 shares in the last quarter. MFA Wealth Advisors LLC acquired a new position in Pfizer during the second quarter worth $29,000. Quarry LP acquired a new position in Pfizer during the second quarter worth $31,000. Finally, Financial Connections Group Inc. acquired a new position in Pfizer during the second quarter worth $34,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Insiders Place Their Bets

In other news, Director Scott Gottlieb acquired 1,000 shares of the firm's stock in a transaction on Wednesday, October 30th. The stock was acquired at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the transaction, the director now owns 10,000 shares in the company, valued at approximately $282,400. The trade was a 11.11 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.06% of the company's stock.

Wall Street Analyst Weigh In

PFE has been the topic of several analyst reports. Citigroup initiated coverage on Pfizer in a research note on Friday, October 25th. They issued a "neutral" rating and a $30.00 target price on the stock. UBS Group boosted their price objective on Pfizer from $30.00 to $31.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 31st. Cantor Fitzgerald reiterated an "overweight" rating and issued a $45.00 price target on shares of Pfizer in a report on Wednesday, October 23rd. Wells Fargo & Company lifted their price target on Pfizer from $28.00 to $30.00 and gave the stock an "equal weight" rating in a report on Wednesday, July 31st. Finally, Barclays boosted their target price on Pfizer from $30.00 to $32.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 31st. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $32.92.

Pfizer Stock Up 2.0 %

PFE stock traded up $0.50 during midday trading on Friday, hitting $25.63. The company's stock had a trading volume of 41,859,420 shares, compared to its average volume of 38,489,203. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The firm's 50-day moving average is $28.21 and its 200-day moving average is $28.57. The company has a market cap of $145.24 billion, a PE ratio of 34.64, a P/E/G ratio of 0.80 and a beta of 0.67. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating analysts' consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm's revenue for the quarter was up 31.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.17) EPS. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be issued a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 6.55%. The ex-dividend date is Friday, November 8th. Pfizer's payout ratio is 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.